peptidesinstitute.org
WEIGHT LOSS

Tirzepatide

Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)

Dual Agonist Peptide for Weight Loss

Buy Tirzepatide
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is Tirzepatide?

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike semaglutide which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors [3], providing a dual mechanism of action for blood sugar control and weight management.

Originally developed for type 2 diabetes and marketed as Mounjaro, tirzepatide has demonstrated remarkable weight loss results in clinical trials. The SURMOUNT trials showed that participants lost up to 22.5% of their body weight over 72 weeks [1], making it one of the most effective weight loss therapies available.

Tirzepatide works by enhancing insulin secretion in a glucose-dependent manner [3], suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways. The dual-agonist approach provides complementary metabolic benefits beyond what single-receptor agonists can achieve.

Research Supply

Source high-purity Tirzepatide for your research

Buy Tirzepatide
Protocol

Dosage Guide

Route: Subcutaneous injection, once weekly

Dosing Schedule

PeriodDose
Weeks 1-42.5 mg
Weeks 5-85.0 mg
Weeks 9-127.5 mg
Weeks 13-1610.0 mg
Weeks 17-2012.5 mg
Week 21+15.0 mg (maximum maintenance)

Reconstitution

VIAL SIZE10 mg
WATER VOLUME2 mL
CONCENTRATION5 mg/mL
Each 0.1 mL (10 units on a U-100 insulin syringe) = 0.5 mg

Injection Volumes

DoseVolumeSyringe Units
2.5 mg0.5 mL50 units
5.0 mg1.0 mL100 units
7.5 mg1.5 mLUse two injections
10.0 mg2.0 mLUse two injections

Administration Tips

  • Inject subcutaneously in the abdomen, thigh, or upper arm
  • Rotate injection sites with each injection
  • Administer on the same day each week
  • Store reconstituted solution refrigerated and use within 28 days
  • Use a standard U-100 insulin syringe for accurate measurement
Safety

Risks & Side Effects

Commonly Reported

Nausea (most common, especially during dose escalation)DiarrheaDecreased appetiteVomitingConstipationAbdominal painDyspepsia (indigestion)Injection site reactions

Serious Risks

Pancreatitis

Acute inflammation of the pancreas; seek medical attention for severe, persistent abdominal pain.

Gallbladder disease

Including gallstones and cholecystitis.

Hypoglycemia

Particularly when used with insulin or sulfonylureas.

Kidney injury

Often secondary to dehydration from gastrointestinal effects.

Allergic reactions

Including potential anaphylaxis.

Thyroid C-cell tumors

Boxed warning based on rodent studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Gastroparesis

Severe slowing of gastric emptying in some individuals.

Related Research

Related Peptides

Expert Voices

Experts Covering Tirzepatide

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Andrew Huberman

PhD -- Stanford Neuroscientist

Jay Campbell

Health Optimization Author and Peptide Advocate

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

Dr. Daniel J. Drucker

MD, FRCPC, FRSC -- GLP-1 Discovery Pioneer

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is tirzepatide?
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist [3] developed by Eli Lilly. Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, it activates two complementary metabolic pathways simultaneously. SURMOUNT trial participants lost up to 22.5% of body weight over 72 weeks, making it one of the most effective weight loss therapies studied.
How does tirzepatide work?
Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 agonism suppresses appetite and slows gastric emptying; GIP agonism improves insulin sensitivity and complements GLP-1's effects on adipose tissue. The dual mechanism produces greater weight loss and glycemic control than either pathway alone, which is reflected in tirzepatide's superior trial outcomes versus GLP-1 monotherapy.
What are tirzepatide side effects?
Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain -- most prominent during dose escalation. Serious risks include pancreatitis, gallbladder disease, hypoglycemia when combined with insulin, and gastroparesis in some individuals. A boxed warning exists for thyroid C-cell tumors based on rodent studies.
What is the tirzepatide dosage for weight loss?
The titration schedule starts at 2.5 mg weekly for four weeks and increases every four weeks: 5 mg, 7.5 mg, 10 mg, 12.5 mg, reaching 15 mg weekly at week 21. This gradual escalation minimizes gastrointestinal side effects. The 15 mg weekly dose represents the maximum maintenance dose studied in the SURMOUNT trials.
Tirzepatide vs semaglutide: which produces more weight loss?
Tirzepatide outperformed semaglutide in clinical data, with SURMOUNT trials showing up to 22.5% body weight reduction versus approximately 15% for semaglutide's STEP trials. The addition of GIP receptor agonism likely accounts for the difference. Both are effective options, and individual response, tolerability, and access should guide the choice.
How long does tirzepatide take to work?
Appetite suppression often begins within the first week or two at the starting dose. Significant weight loss is typically visible by weeks eight to twelve. Maximum average weight loss in clinical trials was observed around week 72. Like semaglutide, tirzepatide's effects diminish after discontinuation, and long-term use is required to maintain results.
Is tirzepatide FDA-approved?
Yes. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes management and as Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. Research-grade tirzepatide without a prescription is used off-label, which carries different regulatory and safety considerations.

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024
  2. Frias JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. PMID 34170647
  3. Willard FS, Douros JD, Gabe MB, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. PMID 32730231

Regulatory & Official Sources